Upper respiratory tract infections have minimal impact on neffy's pharmacokinetics or pharmacodynamics
J Allergy Clin Immunol Pract
.
2024 Mar 6:S2213-2198(24)00263-0.
doi: 10.1016/j.jaip.2024.02.038.
Online ahead of print.
Authors
John Oppenheimer
1
,
Thomas B Casale
2
,
Carlos A Camargo Jr
3
,
David M Fleischer
4
,
David Bernstein
5
,
Richard Lowenthal
6
,
Sarina Tanimoto
7
Affiliations
1
UMDNJ Rutgers University School of Medicine, Newark, NJ.
2
Morsani College of Medicine, University of South Florida, Tampa, Fla.
3
Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.
4
University of Colorado School of Medicine, Aurora, Colo.
5
Division of Immunology and Allergy, University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati, Ohio.
6
ARS Pharmaceuticals, San Diego, Calif.
7
ARS Pharmaceuticals, San Diego, Calif. Electronic address: Sarinat@ars-pharma.com.
PMID:
38458434
DOI:
10.1016/j.jaip.2024.02.038
No abstract available